このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

小児科における肺増悪の合理化された治療 (STOP PEDS RCT)

小児科における肺増悪の合理化された治療ランダム化対照試験 (STOP PEDS RCT)

The STOP PEDS RCT is a multicenter, parallel, open label randomized controlled trial evaluating the long-term (one year) and short-term safety and efficacy of two antibiotic treatment strategies for the management of outpatient pulmonary exacerbations (PEx) in the pediatric CF population.

調査の概要

詳細な説明

The STOP PEDS pilot study demonstrated that a randomized trial of treatment strategies for mild pulmonary exacerbations (PEx) in children with CF was feasible and that assignment to a tailored therapy arm (defined below) may reduce antibiotic exposure.

Based on the research priorities identified by CF families and clinicians and the results of the pilot study, the STOP PEDS RCT is a multicenter, parallel, open label randomized controlled trial evaluating the long-term (one year) and short-term safety and efficacy of two antibiotic treatment strategies for the management of outpatient PEx in the pediatric CF population. The two treatment arms are immediate antibiotics and tailored therapy. In both arms, participants will be instructed to increase airway clearance at the onset of an eligible PEx. In the immediate antibiotics arm, they will also begin 14 days of oral antibiotics preselected by their primary CF providers, while in the tailored therapy they will only begin antibiotics if prespecified criteria for worsening symptoms or failure to improve are met.

The STOP PEDS study will enroll three cohorts. In the main cohort, children ages 6-18 on highly effective modulator therapy (HEMT) will be enrolled when well and followed for 12 months. Participants will be randomly assigned to a treatment arm and maintain that treatment assignment for all subsequent eligible PEx during their 12-month enrollment period. Two additional pilot cohorts, the preschool cohort (children ages 3 to 5 on HEMT) and the non-HEMT cohort (children ages 6-18 not eligible for HEMT), will be enrolled in parallel pilot studies. Participants will enroll when well and be followed through one randomized PEx.

Participants in the STOP PEDS RCT at selected sites will have the opportunity to enroll in optional substudies if eligible. These substudies include:

  • Clinic throat swab substudy
  • Home throat and nasal swab substudy
  • Remote monitoring substudy (Home monitoring of lung function, vital signs, activity and sleep)

研究の種類

介入

入学 (推定)

430

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Erika Enright
  • 電話番号:206-897-1922
  • メール:eenright@uw.edu

研究場所

    • Alabama
      • Birmingham、Alabama、アメリカ、35233
        • 募集
        • The Children's Hospital Alabama & University of Alabama at Birmingham
        • 主任研究者:
          • Christopher Fowler, MD
        • コンタクト:
    • Arizona
      • Tucson、Arizona、アメリカ、85713
        • 募集
        • Tucson Cystic Fibrosis Center
        • 主任研究者:
          • Cori Daines, MD
        • コンタクト:
    • California
      • Los Angeles、California、アメリカ、90027
        • 募集
        • Children's Hospital of Los Angeles & Anton Yelchin Cystic Fibrosis Clinic
        • 主任研究者:
          • Martha McKinney, MD
        • コンタクト:
      • Palo Alto、California、アメリカ、94304
        • 募集
        • Stanford University
        • コンタクト:
        • 主任研究者:
          • Lori WaiHang Lee, MD
      • San Diego、California、アメリカ、92123
        • まだ募集していません
        • Rady Children's Hospital at University of California San Diego
        • コンタクト:
        • 主任研究者:
          • Kathryn Akong, MD
    • Colorado
      • Aurora、Colorado、アメリカ、80045
    • Georgia
      • Atlanta、Georgia、アメリカ、30322
        • 募集
        • Children's Healthcare of Atlanta & Emory University
        • コンタクト:
        • 主任研究者:
          • Ajay Kasi, MD
    • Illinois
      • Chicago、Illinois、アメリカ、60611
        • 募集
        • Ann & Robert H. Lurie Children's Hospital of Chicago & Northwestern University
        • 主任研究者:
          • Maria Dowell, MD
        • コンタクト:
    • Indiana
      • Indianapolis、Indiana、アメリカ、46202
        • 募集
        • Riley Hospital for Children & Indiana University
        • コンタクト:
        • 主任研究者:
          • D. B. Sanders, MD, MS
        • コンタクト:
    • Iowa
      • Iowa City、Iowa、アメリカ、52242
        • 募集
        • University of Iowa
        • コンタクト:
        • 主任研究者:
          • Anthony Fischer, MD
    • Maryland
      • Baltimore、Maryland、アメリカ、21287
        • 募集
        • Johns Hopkins Hospital, Johns Hopkins University
        • コンタクト:
        • 主任研究者:
          • Peter Mogayzel, MD, PhD, MBA
    • Massachusetts
      • Boston、Massachusetts、アメリカ、02115
        • 募集
        • Boston Children's Hospital & Harvard University
        • コンタクト:
        • 主任研究者:
          • Gregory Sawicki, MD
    • Michigan
      • Ann Arbor、Michigan、アメリカ、48109-5212
        • 募集
        • University of Michigan Health System
        • コンタクト:
        • 主任研究者:
          • Samya Nasr, MD
    • Minnesota
      • Minneapolis、Minnesota、アメリカ、55404
        • 募集
        • Children's Hospitals and Clinics of Minnesota
        • 主任研究者:
          • Brooke Moore, MD
        • コンタクト:
      • Minneapolis、Minnesota、アメリカ、55455
        • 募集
        • The Minnesota Cystic Fibrosis Center & University of Minnesota
        • 主任研究者:
          • Samuel Goldfarb, MD
        • コンタクト:
    • Missouri
      • Kansas City、Missouri、アメリカ、64108
        • 募集
        • Children's Mercy Hospital
        • コンタクト:
        • 主任研究者:
          • Hugo Escobar, MD
      • St Louis、Missouri、アメリカ、63110
        • 募集
        • St. Louis Children's Hospital & Washington University School of Medicine
        • 主任研究者:
          • Jessica Pittman, MD
        • コンタクト:
    • New York
      • Rochester、New York、アメリカ、14642
        • 募集
        • University of Rochester Medical Center Strong Memorial
        • コンタクト:
        • 主任研究者:
          • Matthew McGraw, MD
    • North Carolina
      • Chapel Hill、North Carolina、アメリカ、27514
        • 募集
        • University of North Carolina at Chapel Hill
        • 主任研究者:
          • Jennifer Goralski, MD
        • コンタクト:
    • Ohio
      • Cincinnati、Ohio、アメリカ、45229
        • 募集
        • Cincinnati Children's Hospital Medical Center
        • 主任研究者:
          • Gary McPhail, MD
        • コンタクト:
    • Oregon
      • Portland、Oregon、アメリカ、97239-3098
        • 募集
        • Oregon Health & Science University
        • コンタクト:
        • 主任研究者:
          • Kelvin MacDonald, MD
    • Pennsylvania
      • Philadelphia、Pennsylvania、アメリカ、19104
        • 募集
        • Children's Hospital of Philadelphia & University of Pennsylvania
        • 主任研究者:
          • Clement Ren, MD, MBA
        • コンタクト:
        • コンタクト:
      • Pittsburgh、Pennsylvania、アメリカ、15224
        • 募集
        • Children's Hospital of Pittsburgh of UPMC & University of Pittsburgh Medical Center
        • 主任研究者:
          • Daniel Weiner, MD
        • コンタクト:
    • South Carolina
      • Charleston、South Carolina、アメリカ、29425
        • 募集
        • Medical University of South Carolina
        • 主任研究者:
          • Sylvia E Szentpeter, MD
        • コンタクト:
          • Anushka Phadke, CRC
          • 電話番号:843-792-4656
          • メール:phadke@musc.edu
        • コンタクト:
    • Texas
      • Dallas、Texas、アメリカ、75235
        • 募集
        • University of Texas Southwestern & Children's Health
        • 主任研究者:
          • Preeti Sharma, MD
        • コンタクト:
      • Houston、Texas、アメリカ、77030
        • 募集
        • Texas Children's Hospital & Baylor College of Medicine
        • 主任研究者:
          • Fadel Ruiz, MD
        • コンタクト:
    • Vermont
      • Burlington、Vermont、アメリカ、05401
        • 募集
        • Vermont Children's Hospital & University of Vermont Medical Center
        • 主任研究者:
          • Thomas Lahiri, MD
        • コンタクト:
    • Virginia
      • Richmond、Virginia、アメリカ、23298
        • 募集
        • Virginia Commonwealth University
        • コンタクト:
        • 主任研究者:
          • Michael T. Schechter, MD
    • Washington
      • Seattle、Washington、アメリカ、98105
    • Wisconsin
      • Madison、Wisconsin、アメリカ、53792
        • 募集
        • University of Wisconsin
        • 主任研究者:
          • Hara Levy, MD
        • コンタクト:
      • Milwaukee、Wisconsin、アメリカ、53226
        • 募集
        • Children's Wisconsin & Medical College of Wisconsin
        • 主任研究者:
          • Nicholas Antos, MD
        • コンタクト:
    • British Columbia
      • Vancouver、British Columbia、カナダ、V6H 3V4
        • 募集
        • British Columbia Children's Hospital
        • 主任研究者:
          • Jonathan Rayment, MD
        • コンタクト:
    • Ontario
      • Toronto、Ontario、カナダ、M5G 0A4
        • 募集
        • The Hospital for Sick Children & Toronto Canada CF Centre Pediatrics
        • 主任研究者:
          • Felix Ratjen, MD
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

3年~18年 (子、大人)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Age

    1. For main cohort and non-HEMT cohort: age 6 to <19 years
    2. For preschool cohort: age 3 to <6 years
  2. Documentation of a CF diagnosis as evidenced by one or more clinical features consistent with the CF phenotype and one or more of the following criteria:

    1. sweat chloride ≥ 60 mEq/liter
    2. two disease-causing variants in the cystic fibrosis transmembrane conductive regulator (CFTR) gene
  3. Written informed consent (and assent when applicable) obtained from participant or participant's legal representative and ability of participant to comply with the requirements of the study

  4. Highly Effective Modulator Therapy

    1. For main cohort and preschool cohort: Taking HEMT for at least 3 months at enrollment
    2. For non-HEMT cohort: not eligible for HEMT based on CFTR genotype or eligible but not taking for at least 3 months and no plans to start HEMT in the next year, and also not taking tezacaftor-ivacaftor or lumacaftor-ivacaftor for at least 3 months
  5. For main cohort and non-HEMT cohort: able to perform acceptable and reproducible spirometry

  6. For main cohort and non-HEMT cohort: ppFEV1 ≥ 50% predicted at enrollment based on the Global lung Initiative (GLI) reference equations

  7. Ability to receive text messages and access the internet

Exclusion Criteria:

  1. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the individual or the quality of the data
  2. Receiving an acute course of oral or IV antibiotics at the time of enrollment or within the 14 days prior to enrollment. Individuals may be re-screened ≥21 days after completion of antibiotics if they are at their baseline state of health, per self-report
  3. Treatment with systemic corticosteroids at enrollment or within the 14 days prior to enrollment. Individuals may be re- screened ≥21 days after completion of systemic corticosteroids if they are at their clinical baseline, per self-report
  4. History of solid organ transplant
  5. History of positive culture for Mycobacterium abscessus in the 12 months prior to enrollment
  6. Treatment with antibiotics for any non-tuberculous mycobacteria (NTM) at enrollment
  7. Three or more IV antibiotic-treated PEx in the 12 months prior to enrollment
  8. Treatment with chronic oral antibiotics other than azithromycin at enrollment
  9. Treatment with systemic corticosteroids for allergic bronchopulmonary aspergillosis (ABPA) in the 12 months prior to enrollment

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Immediate Antibiotics

Increased airway clearance plus early initiation of oral antibiotics

Increase airway clearance and start 14 days of preselected oral antibiotics right away

実験的:Tailored Therapy

Increased airway clearance alone, with addition of oral antibiotics for worsening symptoms or failure to improve

Increase airway clearance and start preselected oral antibiotics later if symptoms get worse or do not get better according to prespecified criteria

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
One-year change in pulmonary function by spirometry-measured ppFEV1
時間枠:1 year

Compare the difference in pulmonary function between arms by evaluating change in spirometry-measured percent predicted forced expiratory volume (ppFEV1). A spirometry test measures the amount of air a person can forcibly exhale after a deep breath (forced vital capacity, or FVC) and the amount of air they can exhale in one second (forced expiratory volume in one second, or FEV1). A lower measured value compared to the reference value indicates lung disease.

1 year

二次結果の測定

結果測定
メジャーの説明
時間枠
One-Year change in pulmonary function by LCI
時間枠:1 year

Compare the difference in pulmonary function between arms by evaluating change in Lung Clearance Index (LCI). LCI increases when there is lung disease, which causes ventilation inhomogeneity. LCI is calculated as the number of lung volume turnovers (cumulative expired volume divided by the functional residual capacity [FRC]) required to reduce end-tidal nitrogen concentration to 1/40th of the original level.

1 year

その他の成果指標

結果測定
メジャーの説明
時間枠
Recovery to baseline by ppFEV1 and CRISS following a PEx
時間枠:28 days

Compare recovery to baseline between arms over the 28-day period after the first pulmonary exacerbation (PEx), by spirometry-measured percent predicted forced expiratory volume (ppFEV1), and after all pulmonary exacerbations, measured by CRISS symptom scores. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms.

28 days
Recovery to baseline by Lung Clearance Index (LCI)
時間枠:28 days

Compare recovery to baseline between arms over the 28-day period after the first pulmonary exacerbation (PEx) in LCI, and after all exacerbations for symptom scores. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms.

28 days
Safety Endpoint 1: Cumulative oral antibiotic exposure
時間枠:1 year

Compare cumulative oral antibiotic exposure in each treatment arm.

1 year
Safety Endpoint 2: Number of respiratory illnesses
時間枠:1 year

Compare the number of respiratory illnesses reported over the study period in each treatment arm.

1 year
Safety Endpoint 3: Proportion of respiratory illnesses treated with antibiotics during PEx
時間枠:28 days

Compare the proportion of respiratory illnesses treated with antibiotics during the 28-day pulmonary exacerbation (PEx) treatment period in each treatment arm.

28 days
Safety Endpoint 4: Number of PEx treated with IV antibiotics
時間枠:1 year

Compare the number of pulmonary exacerbations (PEx) treated with IV antibiotics over the study period in each treatment arm.

1 year
Safety Endpoint 5: Proportion of PEx failing to recover to baseline symptoms at Day 28
時間枠:28 days

Compare the proportion of pulmonary exacerbations (PEx) failing to recover to baseline symptoms at Day 28 in each treatment arm.

28 days
Safety Endpoint 6: Proportion of PEx with ppFEV1 below baseline at Day 28
時間枠:1 year

Compare the proportion of pulmonary exacerbations (PEx) with spirometry-measured percent predicted forced expiratory volume (ppFEV1) below baseline at Day 28 in each treatment arm.

1 year
Safety Endpoint 7: Time from initial randomized PEx to next respiratory illness
時間枠:1 year

Compare the time from initial randomized pulmonary exacerbation (PEx) to next respiratory illness in each treatment arm.

1 year
Safety Endpoint 8: Targeted adverse events (patient report of antibiotic side effects during PEx)
時間枠:1 year

Compare the targeted adverse events (patient report of antibiotic side effects during pulmonary exacerbation period) in each treatment arm.

1 year
Safety Endpoint 9: Treatment-emergent CF microorganisms on clinical respiratory cultures
時間枠:1 year

Compare treatment-emergent CF microorganisms on clinical respiratory cultures in each treatment arm.

1 year
Qualitative Assessment 1: Caregivers' experience managing study treatment
時間枠:1 year

To understand benefits and challenges associated with assigned treatment through targeted qualitative interviews of caregivers we will describe caregivers' experience managing study treatment and report themes that emerge regarding caregivers' experiences.

1 year
Qualitative Assessment 2: Study treatment impact on child and family daily life
時間枠:1 year

To understand benefits and challenges associated with assigned treatment through targeted qualitative interviews of caregivers we will evaluate study treatment impact on child and family daily life and report themes that emerge regarding caregivers' experiences.

1 year
Health care costs 1: Total estimated cost of antibiotics
時間枠:1 year

Compare total estimated cost of antibiotics used over the course of the study between treatment arms.

1 year
Health care costs 2: Health care utilization
時間枠:1 year

Compare health care utilization over the course of the study between treatment arms, including number of primary care visits and number of emergency room visits.

1 year
Health care costs 3: Parent work productivity measures (WPAI)
時間枠:1 year

To compare parent Work Productivity and Activity Impairment (WPAI) measures between study arms. The WPAI includes four scores assessing absenteeism, presenteeism, work productivity loss (overall work impairment/absenteeism plus presenteeism), and activity impairment in the last seven days. Scores range from 0 to 100, with higher scores indicating greater impairment.

1 year
Preschool and non-HEMT Pilot Cohort Primary Feasibility
時間枠:28 days

Estimate the proportion of preschool and non-HEMT (Highly Effective Modulator Therapy) participants randomized to the tailored therapy arm that has no antibiotic exposure in the 28 days following a pulmonary exacerbation (PEx).

28 days
Preschool and non-HEMT Pilot Cohort Safety Endpoint 1: ppFEV1 and LCI recovery
時間枠:28 days

Compare percent predicted forced expiratory volume (ppFEV1) and Lung Clearance Index (LCI) recovery using Day 28 values compared to nearest pre-PEx baseline measure in both treatment arms.

28 days
Preschool and non-HEMT Pilot Cohort Safety Endpoint 2: Time to symptom recovery
時間枠:28 days

Compare time to symptom recovery (number of days to recover to baseline CRISS score) between treatment arms. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms.

28 days
Preschool and non-HEMT Pilot Cohort Safety Endpoint 3: Targeted adverse events
時間枠:28 days

Compare targeted adverse events (participant report of antibiotic side effects during PEx period) between treatment arms.

28 days
Preschool and non-HEMT Pilot Cohort Safety Endpoint 4: Treatment-emergent CF microorganisms
時間枠:28 days

Compare treatment-emergent CF microorganisms on clinical respiratory cultures between treatment arms.

28 days
Preschool and non-HEMT Pilot Cohort Safety Endpoint 5: Treatment with additional non-protocol assigned antibiotics
時間枠:28 days

Compare treatment with additional non-protocol assigned antibiotics within the 28 days post-randomization between treatment arms.

28 days
Preschool and non-HEMT Pilot Cohort Safety Endpoint 6: Time to IV antibiotics following a randomized PEx
時間枠:28 days

Compare time to IV antibiotics following a randomized PEx (using CF Foundation Patient Registry data, if available) between treatment arms.

28 days
Preschool and non-HEMT Pilot Cohort: Future Larger Clinical Trial Feasibility 1
時間枠:28 days

Measure the proportion of approached patients that enrolls.

28 days
Preschool and non-HEMT Pilot Cohort: Future Larger Clinical Trial Feasibility 2
時間枠:28 days

Measure the proportion of respiratory symptoms meeting randomization criteria.

28 days
Preschool and non-HEMT Pilot Cohort: Future Larger Clinical Trial Feasibility 3
時間枠:28 days

Measure the proportion of respiratory symptoms meeting randomization criteria resulting in treatment initiation within assigned arm.

28 days
Preschool and non-HEMT Pilot Cohort: Future Larger Clinical Trial Feasibility 4
時間枠:28 days

Through targeted qualitative interviews of caregivers we will describe caregivers' experience managing study treatment and report themes that emerge regarding caregivers' experiences in order to understand motivations, benefits and challenges associated with assigned treatment arm.

28 days
Clinic Throat Swab Substudy 1: Metagenomic Sequencing
時間枠:1 year

Use quantitative polymerase chain reaction (qPCR) and metagenomic sequencing to quantitatively define throat swab microbiology at baseline, at exacerbation diagnosis, and after treatment. Metagenomic sequencing analyzes the genomes of all microorganisms in a sample, providing a broad overview of the ecosystem's composition. It can be used to study the diversity of bacteria, detect the abundance of microbes, and study unculturable microorganisms.

1 year
Clinic Throat Swab Substudy 2: Microbiota Measures
時間枠:1 year

Correlate throat microbiota measures (both pre-treatment microbial taxonomic or functional gene abundances, and changes in those abundances) with clinical outcome measures within antibiotic treatments.

1 year
Home Throat and Nasal Swab Substudy 1: Feasibility of Home Collection of Nasal Swabs for Viral Testing and Illness Frequency
時間枠:28 days

Assess the feasibility of home collection of nasal swabs for viral testing at the time of pulmonary exacerbation (PEx) and determine the frequency of viral illness at the time of PEx diagnosis.

28 days
Home Throat and Nasal Swab Substudy 2: Feasibility of Home Collection of Throat Swabs for Bacterial testing
時間枠:28 days

Assess the feasibility of home collection of throat swabs for bacterial testing at the time of pulmonary exacerbation (PEx).

28 days
Home Throat and Nasal Swab Substudy 3: Association Between Viral Illness and Symptom recovery
時間枠:28 days

Evaluate the association between the presence of viral illness and symptom recovery (number of days to recover to baseline CRISS score) between treatment arms. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms.

28 days
Home Throat and Nasal Swab Substudy 3: Association Between Viral Illness and FEV1
時間枠:28 days

Evaluate the association between the presence of viral illness and spirometry-measured forced expiratory volume (FEV1) at Day 28.

28 days
Home Throat and Nasal Swab Substudy 3: Association Between Viral Illness and antibiotic treatment.
時間枠:28 days

Evaluate the association between the presence of viral illness and the percent of subjects in the tailored therapy arm requiring antibiotic treatment.

28 days
Home Throat and Nasal Swab Substudy 5: Bacterial Pathogen Identification, Frequency and Impact on Treatment Changes
時間枠:28 days

Determine the concordance of bacteria identified on CF pathogen testing at the time of pulmonary exacerbation (PEx) compared to the most recent routine clinic visit. In addition, assess how frequently new bacterial pathogens are identified at the time of PEx and how this impacts treatment changes, including the need to change or add antibiotic therapy.

28 days
Remote Monitoring Substudy 1: Feasibility of Home Spirometry Use During PEx
時間枠:28 days

Describe the feasibility and user acceptability of home spirometry during pulmonary exacerbations (PEx) in children with CF via survey of participants at the end of the study.

28 days
Remote Monitoring Substudy 2: Feasibility of BioButton Use During PEx
時間枠:14 days

Describe the feasibility and user acceptability of BioButton use during pulmonary exacerbations in children with CF via survey of participants at the end of the study.

14 days
Remote Monitoring Substudy 3: Change in FEV1 by Home Spirometry
時間枠:28 days

Describe the change from nearest baseline-state FEV1 to Day 0 exacerbation state measurement and the trajectory of change during the exacerbation state (through Day 28).

28 days
Remote Monitoring Substudy 4: Compare Home Spirometry vs. Clinic Spirometry Measures
時間枠:28 days

Compare measurements and their change measured by home spirometry vs. clinic spirometry during the exacerbation state.

28 days
Remote Monitoring Substudy 5: BioButton-measured Change in Resting Heart Rate During PEx
時間枠:14 days

Describe changes in resting heart rate from Day 0 to 14 of the exacerbation state.

14 days
Remote Monitoring Substudy 5: BioButton-measured Change in Resting respiratory rate During PEx
時間枠:14 days

Describe changes in Resting respiratory rate from Day 0 to 14 of the exacerbation state.

14 days
Remote Monitoring Substudy 5: BioButton-measured Change in Activity Level During PEx
時間枠:14 days

Describe changes activity level, measured using actigraphy, and summarized as the mean (SD) number of active minutes in a day, from Day 0 to 14 of the exacerbation state.

14 days
Remote Monitoring Substudy 5: BioButton-measured Change in Sleep During PEx
時間枠:14 days

Describe changes in sleep time from Day 0 to 14 of the exacerbation state.

14 days
Remote Monitoring Substudy 6: Compare BioButton-measured Change in resting heart rate During PEx with Baseline Averages
時間枠:14 days

Compare changes in resting HR to averages from a 7-day period during baseline state.

14 days
Remote Monitoring Substudy 6: Compare BioButton-measured Change in Resting respiratory rate During PEx with Baseline Averages
時間枠:14 days

Compare changes in BioButton-measured Resting respiratory rate to averages from a 7-day period during baseline state.

14 days
Remote Monitoring Substudy 6: Compare BioButton-measured Change in activity level During PEx with Baseline Averages
時間枠:14 days

Compare BioButton-measured change in activity level during pulmonary exacerbation (PEx) to averages from a 7-day period during baseline state.

14 days
Remote Monitoring Substudy 6: Compare BioButton-measured Change in Sleep During PEx with Baseline Averages
時間枠:14 days

Compare BioButton change in sleep during PEx to averages from a 7-day period during baseline state.

14 days
Remote Monitoring Substudy 7: Determine correlations between changes in FEV1 and CRISS to Resting Heart Rate (HR)
時間枠:14 days

Determine correlations between changes from Day 0 to 14 in forced expiratory volume (FEV1) and CRISS score to Resting Heart Rate (HR). The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms.

14 days
Remote Monitoring Substudy 7: Determine correlations between changes in FEV1 and CRISS to Resting Respiratory rate
時間枠:14 days

Determine correlations between changes from Day 0 to 14 in forced expiratory volume (FEV1) and CRISS score to Resting Respiratory rate. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms.

14 days
Remote Monitoring Substudy 7: Determine correlations between changes in FEV1 and CRISS to Activity level
時間枠:14 days

Determine correlations between changes from Day 0 to 14 in forced expiratory volume (FEV1) and CRISS score to Activity level, measured with actigraphy. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms.

14 days
Remote Monitoring Substudy 7: Determine correlations between changes in FEV1 and CRISS to Sleep duration
時間枠:14 days

Determine correlations between changes from Day 0 to 14 in forced expiratory volume (FEV1) and CRISS score to sleep duration. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms.

14 days

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Margaret Rosenfeld, MD, MPH、Seattle Children's Hospital
  • 主任研究者:D. B. Sanders, MD, MS、Indiana University

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2024年12月1日

一次修了 (推定)

2027年12月30日

研究の完了 (推定)

2029年2月28日

試験登録日

最初に提出

2024年10月14日

QC基準を満たした最初の提出物

2024年10月21日

最初の投稿 (実際)

2024年10月23日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月9日

QC基準を満たした最後の更新が送信されました

2026年11月6日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する